Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

This study is testing fourth-generation CAR-T cell therapy — an advanced type of immune cell treatment engineered to target and destroy cancer cells — for adults with blood cancers such as leukemia, lymphoma, and multiple myeloma that have not responded to or recurred after standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have a blood cancer (B-cell leukemia, lymphoma, multiple myeloma, or other blood cancers) with specific surface markers the CAR-T cells can target - You are in reasonably good health (ECOG 0–2) with adequate blood, heart, and organ function - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have previously received CAR-T therapy targeting the same molecule - You are pregnant or breastfeeding - You have had an allogeneic (donor) stem cell transplant - You have active hepatitis B, hepatitis C, HIV, syphilis, or active tuberculosis - You have significant heart disease or uncontrolled diabetes - You have severe psychiatric illness or a serious autoimmune disease Talk to your doctor to see if this trial is right for you.